Skip to content

Efficacy and prognostic factors of botulinum toxin type A microdroplet injection in the treatment of post-facial acne erythema

Efficacy and prognostic factors of botulinum toxin type A microdroplet injection in the treatment of post-facial acne erythema

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098527
Enrollment
Unknown
Registered
2025-03-10
Start date
2023-09-25
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Interventions

Control side:Treatment by Intense Pulsed Light
Experimental side:Intradermal injection of botulinum toxin type A

Sponsors

Henan Provincial People's Hospita,medical
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Both sides of the face suffer from post-acne erythema. 2.Acne condition is stable for more than 1 year. 3.Age: 18 - 40 years;

Exclusion criteria

Exclusion criteria: 1.Scar constitution; 2.Pregnant and lactating women; 3.Those who have recently received sun exposure or are about to receive sun exposure; 4.Those who are taking photosensitizing drugs or have a history of photosensitivity; 5.Patients with severe systemic diseases; 6.Patients with coagulopathy or taking anticoagulants; 7.Patients with Skin tumors; 8.Patients with immunodeficiency diseases;

Design outcomes

Primary

MeasureTime frame
Degree of improvement in erythematous lesions after acne;

Secondary

MeasureTime frame
Skin physiological function test (TEWL, oil, skin water content);

Countries

China

Contacts

Public ContactLi Yang

Henan Provincial People's Hospita,medical

19423427@qq.com+86 15515912211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026